Life Biosciences Announces First-in-Human Phase 1 Trial Data

In a development that could reshape the future of regenerative medicine and ophthalmology, biotechnology pioneer Life Biosciences has released encouraging interim data from its ongoing Phase 1 clinical trial of ER-100. The therapy, designed to test the boundaries of cellular rejuvenation, was administered to three human participants suffering from open-angle glaucoma (OAG). According to the company, a single intravitreal injection of ER-100 coupled with daily oral doxycycline was found to be safe and well-tolerated through Day 56 across all trial subjects. More remarkably, the preliminary evaluations noted early signals of visual field improvement in two of the three participants.

This first-in-human trial—officially registered under identifier NCT07290244—evaluates the groundbreaking application of epigenetic restoration in patients diagnosed with debilitating optic neuropathies. Optic neuropathies represent a severe class of medical conditions characterized by the progressive degradation and ultimate death of retinal ganglion cells (RGCs), which act as the vital neural bridges connecting the light-sensing retina of the eye to the visual processing centers of the brain. Historically, because mammalian RGCs lack the inherent capacity to naturally regenerate, any damage sustained by these cells has been universally classified by the medical community as irreversible, leading inevitably to progressive and permanent vision loss.

The interim findings have already cleared a significant regulatory and safety hurdle. Based on the favorable safety profile observed through the initial 56-day evaluation period, the independent Data Safety Monitoring Board (DSMB) has officially recommended that the trial advance to Dose Level 2. This advancement allows Life Biosciences to escalate the dosage in subsequent participant cohorts, propelling the clinical program forward and bringing researchers one step closer to validating whether epigenetic therapies can successfully treat conditions previously thought to be untreatable.

Understanding the Mechanism of ER-100 and Epigenetic Restoration

At the core of the ER-100 therapeutic approach is Life Biosciences’ proprietary Epigenetic Restoration platform. Unlike conventional treatments for eye diseases—which typically focus on managing symptoms, lowering intraocular pressure (IOP), or slowing the rate of cellular decline—ER-100 aims to target the fundamental root cause of aging at the molecular level.

As living organisms age, cells accumulate epigenetic modifications—chemical tags and structural changes to DNA and histones—that alter gene expression without changing the underlying genetic code. These accumulated epigenetic errors cause cells to lose their youthful identity, functional efficiency, and resilience against stress and disease. To reverse this cellular aging process, ER-100 utilizes a controlled, inducible system that delivers three specific transcription factors: OCT4, SOX2, and KLF4, collectively known as OSK.

When introduced into damaged or aged cells, the controlled expression of OSK functions essentially as a cellular reset button. It reprograms the epigenetic landscape of the cell, effectively erasing harmful age-associated markers and guiding the cell back to a more youthful, functionally competent state. In the context of ER-100, this technology is harnessed specifically to restore the health and operational capacity of retinal ganglion cells that have been compromised by chronic neurodegenerative processes or acute ischemic events.

In the design of the Phase 1 trial, ER-100 is delivered via a single intravitreal injection directly into the vitreous body of the eye using an adeno-associated virus vector (AAV-2). To ensure safety and precise control, the expression of the OSK transcription factors is not left active indefinitely; instead, it is conditionally regulated by systemic administration of oral doxycycline administered daily over an eight-week (56-day) period. Furthermore, because introducing viral vectors and foreign gene sequences can sometimes trigger a localized immune reaction, patients concurrently receive a carefully managed oral prednisolone taper to minimize the risk of intraocular inflammation.

Chronology and Clinical Trial Design

The journey toward this clinical milestone has been years in the making, reflecting a meticulous path from foundational academic discoveries in cellular reprogramming to rigorous preclinical testing and, ultimately, human translation.

The underlying science of OSK-mediated epigenetic rejuvenation gained global prominence through pioneering research demonstrating that Yamanaka factors could safely reverse cellular aging in various tissues without inducing dedifferentiation into pluripotent stem cells. Building upon these breakthroughs, Life Biosciences spent years optimizing the delivery, control, and safety parameters of the technology specifically for ocular applications.

In the first quarter of 2026, the company officially initiated its landmark Phase 1, open-label, first-in-human clinical trial (NCT07290244). Designed primarily as a safety and tolerability study, the trial enrolls adult participants diagnosed with severe optic neuropathies. Over the critical 56-day evaluation window, patients undergo a battery of rigorous clinical examinations, including comprehensive ophthalmic evaluations, intraocular pressure checks, systemic safety panels, and sophisticated visual field testing designed to map out functional vision capabilities.

The release of these interim data points represents the first clinical readouts from that trial. The fact that the Data Safety Monitoring Board has endorsed an immediate escalation to Dose Level 2 signals that the safety margins demonstrated at the initial dosing tier were satisfactory, paving the way for expanded exploration.

Clinical Perspectives and Leadership Commentary

The medical and scientific leadership at Life Biosciences has expressed measured optimism regarding these early clinical findings, emphasizing both the achievement of safety milestones and the unexpected, yet encouraging, preliminary signs of functional efficacy.

“These initial results provide early information regarding the tolerability of ER-100 and epigenetic restoration in people with open angle glaucoma,” said Sharon Rosenzweig-Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “We are encouraged by the Data Safety Monitoring Board’s recommendation to escalate to Dose Level 2, a decision that allows us to keep moving this trial forward on behalf of people living with optic neuropathies like glaucoma, a disease where vision loss is often considered irreversible.”

Dr. Rosenzweig-Lipson further highlighted the significance of the visual field observations, noting that while the primary objective of a Phase 1 study is invariably to establish safety profiles and identify any adverse events, observing potential functional improvements in two of the trial participants provides a compelling rationale for the continued advancement of the program. “This milestone marks an important step in Life Bio’s progress translating epigenetic restoration into a new class of medicines for age-related diseases,” she added.

Broader Medical Context: The Burden of Open-Angle Glaucoma and NAION

To fully appreciate the significance of the ER-100 trial, it is necessary to examine the profound medical burden imposed by optic neuropathies on aging populations globally.

Open-angle glaucoma is a chronic, progressive neurodegenerative condition that stands as one of the leading causes of irreversible blindness among older adults worldwide. Characterized by the gradual degeneration of retinal ganglion cells, OAG is frequently associated with elevated intraocular pressure inside the eye. However, ophthalmologists note that lowering intraocular pressure—currently the cornerstone of all standard glaucoma treatments—often fails to halt the progression of the disease in many patients. Furthermore, a significant subset of patients develops and suffers from normal-tension glaucoma, where optic nerve damage occurs despite normal intraocular pressures. This underscores a desperate medical need for neuroprotective and neuro-restorative therapies that can rescue damaged neural tissue regardless of pressure dynamics.

Beyond glaucoma, Life Biosciences is positioning ER-100 to address other devastating optic conditions, such as non-arteritic anterior ischemic optic neuropathy (NAION). NAION is the single most common acute optic neuropathy affecting adults over the age of fifty. It is characterized by a sudden, painless loss of vision caused by localized ischemia—an insufficient supply of blood and oxygen to the optic nerve head. Currently, modern medicine has zero FDA-approved treatments capable of reversing or effectively treating the acute vision loss associated with NAION, leaving patients with permanent visual impairment.

Implications for the Future of Age-Related Medicine

The implications of Life Biosciences’ ongoing clinical trial extend far beyond ophthalmology. If the Epigenetic Restoration platform continues to demonstrate safety and hints of efficacy in human trials, it could fundamentally alter the pharmaceutical industry’s approach to human longevity and age-related pathologies.

Aging has traditionally been viewed as an inevitable, entropic decline of biological systems—a complex web of wear and tear that can, at best, be slowed down through lifestyle modifications or managed symptomatically via pharmaceuticals. Epigenetic restoration challenges this paradigm by suggesting that cellular aging is not merely structural damage, but an information problem: the cell retains the genetic blueprint for youthful function, but the software running that blueprint has become corrupted by epigenetic noise. By utilizing temporary, controlled expression of transcription factors to rewrite this epigenetic software, therapeutics like ER-100 demonstrate that cells can recover lost functionality.

As the ER-100 Phase 1 trial progresses to Dose Level 2 and gathers further data regarding longer-term safety and visual outcomes, the broader scientific community will be watching closely. Success in these early-stage trials could unlock a tidal wave of innovation aimed at applying epigenetic reprogramming to other intractable age-related diseases, ranging from cardiovascular degeneration to neurodegenerative disorders of the central nervous system.

For the millions of patients currently facing the prospect of permanent blindness due to glaucoma and other optic neuropathies, the advancement of ER-100 offers a glimmer of hope where none previously existed—transforming theoretical biogerontology into tangible, life-changing medicine.